Skip to main content

Modern approaches for developing antivirals against SARS-CoV 2

Project description

Coordinated multi-disciplinary effort to develop therapy against coronavirus outbreaks

Response to the SARS-CoV-2 pandemic and future coronavirus outbreaks requires an organised effort and the rapid translation of scientific findings to industry partners. The EU-funded MAD-CoV 2 project has assembled a multi-disciplinary team of researchers and innovative industry partners to study the virus infections in host cells and rapidly translate knowledge into new medicines and public health measures. Angiotensin-converting enzyme 2 (ACE2) is a promising drug target for treating cardiovascular diseases and also serves as the cell entry point for some coronaviruses. The objectives of MAD-CoV 2 are to uncover the role of ACE2 in viral replication and COVID-19 pathogenesis and translate this knowledge into novel therapies to fight coronavirus outbreaks. Moreover, the project will develop new strategies for developing antivirals against SARS-CoV2 and other emerging viral diseases.

Call for proposal

H2020-JTI-IMI2-2020-21-single-stage
See other projects for this call

Coordinator

STATENS VETERINAERMEDICINSKA ANSTALT
Address
Ulls Vaeg 2B
75189 Uppsala
Sweden
Activity type
Research Organisations
EU contribution
€ 1 299 931,25

Participants (8)

INSERM TRANSFERT SA
France
EU contribution
€ 249 875
Address
Rue Watt 7
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH
Austria
EU contribution
€ 1 100 000
Address
Dr Bohrgasse 3
1030 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
JUSTUS-LIEBIG-UNIVERSITAET GIESSEN
Germany
EU contribution
€ 600 000
Address
Ludwigstrasse 23
35390 Giessen
Activity type
Higher or Secondary Education Establishments
JLP HEALTH GMBH
Austria
EU contribution
€ 0
Address
Himmelhofgasse 62
1130 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
APEIRON BIOLOGICS AG
Austria
EU contribution
€ 0
Address
Campus-vienna-biocenter 5
1030 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
Spain
EU contribution
€ 499 862,50
Address
Carrer Baldiri Reixac Planta 2A 10-12
08028 Barcelona
Activity type
Research Organisations
STEMCELL TECHNOLOGIES UK LTD
United Kingdom
EU contribution
€ 0
Address
Building 7100 Cambridgde Research Park Beach Drive Waterbeach
CB25 9TL Cambridge
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
VIRONOVA AB
Sweden
EU contribution
€ 0
Address
Gavlegatan 22
113 30 Stockholm
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)